Tesamorelin
Evidence: A/D — Established Human EvidenceGH Axis / Body Composition
Evidence Snapshot
What this grade covers
A: The exact FDA-approved indication—reduction of excess abdominal fat in adults with HIV-associated lipodystrophy—supported by regulated-product labeling and randomized phase 3 trials. B: Selected liver-fat and NAFLD findings in people with HIV, which remain population-specific and off-label. D: General weight loss, obesity treatment, anti-aging, bodybuilding, athletic performance, cognition, longevity, and unrelated wellness uses.
Regulatory Context
EGRIFTA WR and EGRIFTA SV are FDA-approved for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. They are not indicated for weight management and are not substitutable. Their formulation, dosing, reconstitution, storage, safety, and efficacy evidence applies to the exact labeled products—not to unrelated vendor vials or same-vial blends.
Research Takeaway
Tesamorelin is a synthetic human growth hormone-releasing factor analogue; FDA labeling for EGRIFTA formulations describes tesamorelin as an acetate salt derived from the 44-amino-acid human GRF sequence with an N-terminal trans-3-hexenoyl modification.
See all 15 evidence claims →Quick Summary
Tesamorelin is an FDA-approved growth hormone-releasing hormone analogue for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Randomized trials support reduction of visceral adipose tissue in that specific population, with additional population-specific research on liver fat. It is not indicated for general weight loss, and evidence does not establish anti-aging, bodybuilding, cognitive, athletic, or longevity benefits.
Mechanism & Research Overview
Tesamorelin is a synthetic analogue of human growth hormone-releasing factor, also called growth hormone-releasing hormone. It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells and stimulates endogenous growth hormone secretion. The resulting growth-hormone signal increases circulating insulin-like growth factor 1 and IGF-binding protein 3.
Read more about the mechanism
The approved prescribing information describes growth-hormone secretion as pulsatile rather than continuous. Growth hormone acts directly through receptors in tissues including liver, muscle, bone, and adipose tissue, while some downstream effects are mediated through IGF-1. Clinical reductions in visceral adipose tissue cannot be assumed to represent equivalent loss of subcutaneous fat, overall body weight, or fat in every population.
After subcutaneous administration, tesamorelin is absorbed rapidly and has a short plasma elimination half-life. A short circulating half-life does not mean that downstream growth-hormone or IGF-1 effects end immediately. Human pharmacokinetic data are formulation- and population-specific, and approved-product findings should not be transferred to unrelated compounded or research-use preparations.
Evidence Grade Breakdown
A single letter grade can't capture how evidence quality differs across approved use, off-label use, and unsupported claims. The categories below break that down -- none of them grade this compound "overall."
Overall Research Grade
Tesamorelin has high-quality FDA-label and randomized human evidence for the exact approved indication of reducing excess abdominal fat in adults with HIV-associated lipodystrophy, with population-specific off-label liver-fat evidence in people with HIV. The same evidence does not establish general obesity treatment, anti-aging, bodybuilding, athletic-performance, cognition, longevity, or unrelated wellness use.
AApproved-Indication Evidence
Confidence: High
Scope: Applies only to the regulated indication, studied population, and approved product formulations.
Show detail
Approved-Indication Evidence
Tesamorelin has FDA-approved prescribing information and randomized phase 3 evidence supporting reduction of excess abdominal fat in adults with HIV-associated lipodystrophy.
Why this grade
- FDA approved EGRIFTA and EGRIFTA SV (tesamorelin) for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy.
- Approval was based on randomized, placebo-controlled phase 3 trials meeting their primary visceral adipose tissue endpoints.
- Current FDA prescribing information for both EGRIFTA and EGRIFTA SV remains in effect and describes the approved indication.
- Efficacy findings were replicated across multiple independent randomized trials in the approved population.
- Regulatory approval required demonstrated efficacy and an evaluated safety profile specific to this indication.
Important limitations
- Applies only to the FDA-approved indication, studied population, and approved product formulations.
- Does not extend to other causes of abdominal fat accumulation outside HIV-associated lipodystrophy.
- Requires prescription use under medical supervision consistent with the approved labeling.
A-Human Clinical Evidence
Confidence: High
Show detail
Human Clinical Evidence
Multiple randomized controlled trials support reduction of visceral adipose tissue in adults with HIV-associated lipodystrophy. Additional human trials support liver-fat effects in selected people with HIV, but those findings remain population-specific and off-label.
Why this grade
- Randomized, placebo-controlled phase 3 trials demonstrated reduction of visceral adipose tissue in adults with HIV-associated lipodystrophy.
- Trial findings were consistent across the pivotal 26-week and long-term 52-week extension study periods.
- A separate randomized controlled trial found reduced liver fat in a population with HIV and elevated liver fat.
- A further randomized trial reported liver-fat effects in people with HIV and non-alcoholic fatty liver disease.
- All primary human trials in the canonical evidence graph are randomized and controlled, not observational.
Important limitations
- The visceral-fat trials studied a specific population: adults with HIV-associated lipodystrophy, not the general population.
- Liver-fat findings come from smaller, population-specific trials and have not been used to support an FDA indication.
- No randomized trial evidence supports use in people without HIV-associated lipodystrophy for the studied endpoints.
- Long-term outcomes beyond the studied trial durations have not been established.
AMechanistic Evidence
Confidence: High
Show detail
Mechanistic Evidence
The GHRH-receptor mechanism, endogenous pulsatile growth-hormone release, and downstream IGF-1 and IGFBP-3 effects are well characterized in prescribing information and clinical pharmacology research.
Why this grade
- Tesamorelin is a GHRH analog with a well-characterized mechanism of binding the pituitary GHRH receptor.
- GHRH-receptor binding stimulates endogenous, pulsatile growth-hormone release rather than direct hormone replacement.
- Downstream IGF-1 and IGFBP-3 increases are documented in clinical pharmacology data included in FDA labeling.
- The mechanism is consistent with the drug class's established pharmacology for other GHRH analogs.
- Pharmacokinetic and pharmacodynamic properties are described in detail in the approved prescribing information.
Important limitations
- A well-characterized mechanism does not by itself establish efficacy or safety for uses outside the approved indication.
- Mechanistic plausibility for other proposed uses (e.g. general anti-aging effects) has not been clinically demonstrated.
B+Safety Evidence
Confidence: High
Show detail
Safety Evidence
Clinical trials and regulated labeling describe common adverse effects, contraindications, IGF-1 elevation, glucose intolerance, fluid retention, hypersensitivity, malignancy concerns, and pituitary-axis restrictions. Long-term cardiovascular safety remains unresolved.
Why this grade
- Adverse-effect rates and types are documented from randomized controlled trials in the approved indication.
- FDA labeling specifies contraindications, including active malignancy and hypersensitivity to tesamorelin.
- Labeling documents IGF-1 elevation, glucose intolerance, and fluid retention as expected class-related effects.
- Pituitary-axis and hypersensitivity precautions are specified in the regulated prescribing information.
- Safety monitoring recommendations (e.g. IGF-1 levels, glucose) are defined in the approved labeling.
Important limitations
- Long-term cardiovascular safety beyond studied trial durations has not been established.
- Safety data reflect the studied population and may not generalize to other populations or longer-term use.
- Safety findings do not address unsupervised, off-label, or unapproved-formulation use.
DOff-Label Evidence
Confidence: Moderate
Show detail
Off-Label Evidence
Evidence outside HIV-associated lipodystrophy is limited and population-specific. Findings involving liver fat do not establish a general indication for obesity, MASLD, MASH, liver fibrosis, or metabolic disease.
Why this grade
- A randomized controlled trial reported reduced liver fat in a population with HIV and elevated liver fat.
- A separate randomized trial reported liver-fat effects in people with HIV and non-alcoholic fatty liver disease.
- These findings come from the same canonical trial evidence used to grade Human Clinical Evidence above.
Important limitations
- Findings are limited to specific HIV-positive, liver-fat-affected populations, not the general population.
- No trial evidence establishes tesamorelin as a treatment for obesity, MASLD, MASH, or liver fibrosis broadly.
- None of these findings have been used to support an additional FDA-approved indication.
- Off-label use has not been evaluated for long-term safety or efficacy outside the studied trial populations.
FBiohacking and Wellness Claims
Confidence: Moderate
Show detail
Biohacking and Wellness Claims
Current evidence does not establish tesamorelin as an anti-aging, longevity, bodybuilding, athletic-performance, cognitive-enhancement, or general wellness intervention.
Why this grade
- No randomized controlled trial in the canonical evidence graph studied anti-aging or longevity endpoints.
- No randomized controlled trial studied bodybuilding, athletic-performance, or cognitive-enhancement endpoints.
- FDA-approved labeling does not describe or support any wellness, longevity, or performance-related use.
- All primary trial evidence is confined to the HIV-associated lipodystrophy and related liver-fat populations.
- Marketing claims describing these uses are not supported by the reviewed regulatory or clinical trial evidence.
Important limitations
- Absence of supporting evidence is not the same as evidence of ineffectiveness for every conceivable use.
- This grade reflects the current reviewed evidence base and could change if new trial data becomes available.
Evidence reviewed
Covers the canonical Tesamorelin evidence graph: current FDA prescribing information for EGRIFTA WR and EGRIFTA SV and four randomized controlled human trial publications addressing the approved HIV-associated lipodystrophy indication and population-specific liver-fat findings. Contextual reviews and historical predecessor labels are excluded from the canonical count.
- Randomized human trials
- 4
- Regulatory documents
- 2
- Primary sources reviewed
- 6
- Last literature review
- August 9, 2026
Study counts describe the reviewed evidence base. They do not independently determine evidence quality.
How MitoCore grades evidence
Grade definitions
- A
- Strong and directly applicable evidence, generally including regulatory support or multiple high-quality replicated human trials for the exact claim and population.
- A-
- Strong human evidence with limited uncertainty, narrower applicability, or incomplete replication.
- B+
- Moderately strong evidence with meaningful human support but important scope, duration, safety, or generalizability limitations.
- B
- Credible evidence with notable uncertainty, limited replication, or mixed results.
- C
- Preliminary or inconsistent evidence, usually limited human data or strong indirect evidence.
- D
- Weak, indirect, population-limited, or largely unsupported evidence for the specific use being graded.
- F
- No credible supporting evidence, evidence contradicting the claim, or claims based primarily on speculation or marketing.
Confidence definitions
- High
- The evidence classification is unlikely to change substantially with ordinary additional research.
- Moderate
- The classification is reasonably supported but could change with additional high-quality evidence.
- Low
- The evidence base is sparse, indirect, inconsistent, or dependent on uncertain assumptions.
- Very Low
- The evidence base is extremely limited, speculative, or unsuitable for firm conclusions.
Scope
The grade evaluates the evidence supporting the specific category or claim. A grade does not evaluate product purity, supplier quality, personal suitability, treatment appropriateness, individual outcomes, legality, or medical safety for a specific person.
These grades and confidence levels describe the research evidence itself. They are not medical recommendations, and they do not evaluate any specific product, supplier, or individual's situation.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Tesamorelin is a synthetic human growth hormone-releasing factor analogue; FDA labeling for EGRIFTA formulations describes tesamorelin as an acetate salt derived from the 44-amino-acid human GRF sequence with an N-terminal trans-3-hexenoyl modification.
Sources: EGRIFTA WR- tesamorelin kit; EGRIFTA SV- tesamorelin kit
Supported
EGRIFTA WR is FDA approved to reduce excess abdominal fat in HIV-infected adult patients with lipodystrophy.
Sources: EGRIFTA WR- tesamorelin kit
Supported
Randomized clinical trials in HIV-associated abdominal fat accumulation show that tesamorelin reduces visceral adipose tissue.
Sources: Metabolic effects of a growth hormone-releasing factor in patients with HIV; Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension; Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
Supported
Pooled Phase 3 data show that visceral-fat reduction can be maintained with continued tesamorelin treatment, while longer-term program data indicate that effects are not necessarily sustained after treatment withdrawal.
Sources: Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data; Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation
Supported
In a randomized six-month study of HIV-infected patients with abdominal fat accumulation, tesamorelin reduced visceral fat and produced a modest reduction in liver fat.
Supported
A one-year randomized trial in people with HIV and NAFLD found a greater reduction in hepatic fat fraction and less fibrosis progression with tesamorelin than placebo, but the findings remain population-specific and do not establish an approved general-NAFLD or MASH indication.
Supported
Tesamorelin's clinical effect is primarily a change in visceral adipose tissue rather than a general reduction in body weight; the approved label describes it as weight neutral.
Sources: EGRIFTA WR- tesamorelin kit; Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension
Supported
Current evidence does not establish cardiovascular-event reduction, mortality benefit, improved antiretroviral adherence, cognitive enhancement, athletic enhancement, bodybuilding benefit, anti-aging benefit, or longevity benefit.
Sources: EGRIFTA WR- tesamorelin kit
Supported
Clinical trial and label evidence is specific to regulated EGRIFTA formulations and cannot establish the identity, purity, sterility, stability, dosing equivalence, or clinical performance of compounded, research-use, or same-vial combination products.
Sources: EGRIFTA WR- tesamorelin kit; EGRIFTA SV- tesamorelin kit
Supported
Tesamorelin increases IGF-1, and the prescribing information recommends monitoring because the effects of prolonged IGF-1 elevation are unknown.
Sources: EGRIFTA WR- tesamorelin kit; EGRIFTA SV- tesamorelin kit
Supported
Current EGRIFTA WR labeling identifies clinically important risks and monitoring issues including malignancy considerations, elevated IGF-1, fluid retention, glucose intolerance or diabetes, hypersensitivity, and injection-site reactions.
Sources: EGRIFTA WR- tesamorelin kit; EGRIFTA SV- tesamorelin kit
Supported
EGRIFTA WR is contraindicated in patients with disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity to tesamorelin or product excipients, and pregnancy.
Sources: EGRIFTA WR- tesamorelin kit; EGRIFTA SV- tesamorelin kit
Supported
The current EGRIFTA WR label explicitly states that EGRIFTA WR is not indicated for weight-loss management.
Sources: EGRIFTA WR- tesamorelin kit
Supported
EGRIFTA WR and EGRIFTA SV are distinct formulations with different dosage and administration instructions and are not substitutable.
Sources: EGRIFTA WR- tesamorelin kit; EGRIFTA SV- tesamorelin kit
Supported
Any tesamorelin dose, route, reconstitution, or administration information published on the site must be explicitly tied to the exact FDA-labeled formulation or a named clinical trial and must not be presented as a general peptide protocol.
Sources: EGRIFTA WR- tesamorelin kit; EGRIFTA SV- tesamorelin kit; Metabolic effects of a growth hormone-releasing factor in patients with HIV; Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Higher-Priority Safety Consideration
Tesamorelin increases growth hormone and IGF-1. The prescribing information states that the effects of prolonged IGF-1 elevation are unknown and recommends monitoring, with consideration of discontinuation for persistent marked elevation.Higher-Priority Safety Consideration
Active malignancy and disruption of the hypothalamic-pituitary axis are contraindications. A history of malignancy requires careful risk-benefit assessment because tesamorelin induces endogenous growth hormone release.Higher-Priority Safety Consideration
Pregnancy is contraindicated. Safety and effectiveness are not established for pediatric use, and information is limited in adults older than 65 years and in many populations outside the approved HIV-lipodystrophy indication.Higher-Priority Safety Consideration
Approved-product evidence cannot verify unapproved or compounded tesamorelin products. Identity, strength, sterility, excipients, reconstitution, storage, and clinical equivalence may differ materially.Safety Consideration
Tesamorelin can worsen glucose tolerance or contribute to diabetes. Labeling recommends glucose assessment before and during treatment and additional attention to retinopathy risk in people with diabetes.Safety Consideration
Edema, arthralgia, musculoskeletal discomfort, and carpal-tunnel symptoms can occur and are considered related to induced growth-hormone secretion.Safety Consideration
Clinical studies reported hypersensitivity and injection-site reactions. Anti-tesamorelin antibodies were common in the original clinical program, although their clinical significance was not fully established.Safety Consideration
Long-term cardiovascular safety has not been established. Reduction in visceral fat or improvement in selected biomarkers must not be presented as proof of fewer cardiovascular events or longer survival.
Research Areas Being Studied
Research areas discussed on this page reflect the GH Axis / Body Composition category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial (2019): One-year randomized, double-blind trial found greater reduction in hepatic fat fraction and less fibrosis progression than placebo.
- Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial (2014): Six-month randomized trial found reduction in visceral adipose tissue and a modest reduction in liver fat compared with placebo.
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data (2010): Daily tesamorelin or placebo for 26 weeks, followed by 26-week extension phases; continued treatment better maintained visceral-fat reduction than switching to placebo.
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension (2010): visceral adipose tissue decreased 10.9% (-21 cm2) vs 0.6% (-1 cm2) with placebo; effect sustained at 12 months.
- Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation (2008):
- Metabolic effects of a growth hormone-releasing factor in patients with HIV (2007): Randomized, placebo-controlled 26-week trial of daily subcutaneous tesamorelin; visceral adipose tissue was the primary efficacy endpoint.
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial | 2019 | 61 adults with HIV and NAFLD | One-year randomized, double-blind trial found greater reduction in hepatic fat fraction and less fibrosis progression than placebo. | Injection-site complaints were more frequent with tesamorelin; sample size limits precision for uncommon risks. | |
| Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial | 2014 | Adults with HIV and abdominal-fat accumulation | Six-month randomized trial found reduction in visceral adipose tissue and a modest reduction in liver fat compared with placebo. | Preliminary sample size and duration limit conclusions about clinical liver outcomes and uncommon adverse events. | |
| Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data | 2010 | 806 antiretroviral-treated adults with HIV and excess abdominal fat, pooled across two phase 3 trials (543 tesamorelin / 263 placebo) | Daily tesamorelin or placebo for 26 weeks, followed by 26-week extension phases; continued treatment better maintained visceral-fat reduction than switching to placebo. | Long-term cardiovascular outcomes were not established; label-based glucose, IGF-1, fluid-retention, hypersensitivity, and injection-site precautions remain relevant. | |
| Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension | 2010 | 404 antiretroviral-treated adults with HIV and excess abdominal fat | Daily subcutaneous tesamorelin vs placebo, randomized 2:1, for 6 months with a 6-month safety extension — visceral adipose tissue decreased 10.9% (-21 cm2) vs 0.6% (-1 cm2) with placebo; effect sustained at 12 months. | Human data; interpret within the studied population, dose, duration, and endpoints. Review full paper for adverse events and exclusions. | |
| Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation | 2008 | Longer-term follow-up from the HIV lipodystrophy development program showed that visceral-fat effects depended on continued treatment and added safety experience beyond the initial blinded period. | |||
| Metabolic effects of a growth hormone-releasing factor in patients with HIV | 2007 | 412 adults with HIV and excess abdominal fat | Randomized, placebo-controlled 26-week trial of daily subcutaneous tesamorelin; visceral adipose tissue was the primary efficacy endpoint. | Adverse-event withdrawals and glucose, IGF-1, edema, hypersensitivity, and injection-site findings require interpretation from the full trial and label. |
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| EGRIFTA SV- tesamorelin kit | 2025 | FDA-approved EGRIFTA SV product for adults with HIV-associated lipodystrophy | Current formulation-specific prescribing information for EGRIFTA SV. EGRIFTA SV and EGRIFTA WR differ in strength, labeled dose, preparation, storage, and administration and are not substitutable. | The prescribing information applies only to the FDA-approved EGRIFTA SV product and does not validate unrelated, compounded, research-use, vendor, or combination products. | |
| EGRIFTA WR- tesamorelin kit | 2025 | FDA-approved EGRIFTA WR product for adults with HIV-associated lipodystrophy | Current prescribing information for the 11.6 mg-per-vial EGRIFTA WR formulation; the labeled dose is 1.28 mg subcutaneously once daily. EGRIFTA WR and EGRIFTA SV have different strengths, labeled doses, preparation, storage, and administration requirements and are not substitutable. | Long-term cardiovascular safety has not been established. The prescribing information is specific to the FDA-approved EGRIFTA WR product and does not establish safety, efficacy, dosing, or interchangeability for compounded, research-use, vendor, or combination products. |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Modern INSTI-era tesamorelin analysis | 2024 | People with HIV | Clinical trial/review context — Supports visceral fat effects in modern antiretroviral era; notes tesamorelin is approved for this HIV indication. | Secondary source; useful for context but not a substitute for primary study review. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Tesamorelin's grade A evidence applies to the exact approved HIV-lipodystrophy indication and labeled products. It does not establish a general weight-loss, bodybuilding, anti-aging, or same-vial combination benefit.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Website/CMS content draft; source verification and legal/privacy review required before public launch. Last updated 2026-07-20.
Follow research updates for Tesamorelin
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.